Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Valuation & Earnings
This table compares Compass Therapeutics and Immatics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compass Therapeutics | $850,000.00 | 480.95 | -$66.49 million | ($0.41) | -5.54 |
| Immatics | $37.30 million | 35.77 | -$222.26 million | ($1.99) | -5.00 |
Volatility and Risk
Compass Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.
Profitability
This table compares Compass Therapeutics and Immatics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -39.75% | -35.29% |
| Immatics | -572.35% | -47.36% | -39.35% |
Analyst Recommendations
This is a summary of recent recommendations for Compass Therapeutics and Immatics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 1 | 1 | 12 | 1 | 2.87 |
| Immatics | 1 | 1 | 6 | 0 | 2.62 |
Compass Therapeutics presently has a consensus price target of $12.25, indicating a potential upside of 439.65%. Immatics has a consensus price target of $20.80, indicating a potential upside of 109.05%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Compass Therapeutics is more favorable than Immatics.
Insider and Institutional Ownership
68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Compass Therapeutics beats Immatics on 12 of the 15 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
